NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury

Executive Summary

• The Board of Directors appointed Dr. Adam Rogers as President and Chief Executive Officer, effective immediately.
• Dr. Rogers’ appointment follows his successful interim tenure, during which the company completed its Nasdaq listing and advanced NVG‑291 toward late‑stage development.
• Concurrent with the appointment, the Company granted Dr. Rogers 717,891 stock options at exercise prices of US $5.06 (614,799 options) and US $5.57 (103,092 options), vesting over four years.

Key Details

• Appointment: Adam Rogers, MD – previously Interim CEO and Board member since July 2022 – is now President & CEO.
• Rationale: Board cited his “decisive execution against key milestones,” including the Nasdaq listing and progress of NVG‑291.
• Option Grant:
• Total options granted: 717,891.
• Vesting schedule: 25 % on first anniversary; remaining 75 % in equal monthly installments over the next 36 months, contingent on continued service.
• Exercise prices & terms:
  • 614,799 options at US $5.06 per share, exercisable for ten years from grant date.
  • 103,092 options at US $5.57 per share, exercisable for five years from grant date.
• Company Context: NervGen is a clinical‑stage biopharma developing NVG‑291 (neuroreparative peptide) for spinal cord injury; the candidate has Fast Track (FDA) and Orphan Drug (EMA) designations and is moving toward Phase 3 trials.
• Leadership Background: Dr. Rogers is a board‑certified ophthalmologist, principal at PFP Biosciences Holdings, co‑founder of Hemera Biosciences (acquired by Janssen), and former Assistant Professor of Ophthalmology at Tufts Medical Center.

Notable Quotes

• Craig Thompson, Independent Director: “Adam exemplifies the leadership qualities that NervGen requires…bringing the unique perspective of a practicing physician and seasoned biotech executive.”
• Adam Rogers, MD, CEO: “We are at a point in the Company’s growth where focus, discipline, and execution matter more than ever…”